Conference Report: Immunogenicity: Prediction, detection and effective assay development

Bioanalysis

Volumn 2, Issue 9, 2010, Pages 1539-1545

  Gorovits, Boris ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8 ANTIBODY; DRUG ANTIBODY; EPITOPE; GALSULFASE; HLA ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHENYLALANINE 4 MONOOXYGENASE; RECOMBINANT BLOOD CLOTTING FACTOR 8; ANTIBODY; BIOLOGICAL PRODUCT; DRUG;

ANALYTIC METHOD; ANTIBODY DETECTION; ANTIGEN BINDING; B LYMPHOCYTE ACTIVATION; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME REPLACEMENT; HLA TYPING; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; NONHUMAN; PHENYLKETONURIA; PRACTICE GUIDELINE; PREDICTION; PROCESS DEVELOPMENT; PROTEIN AGGREGATION; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; WORKSHOP; ANIMAL; DRUG INDUSTRY; IMMUNOLOGY; METHODOLOGY; PHARMACOKINETICS; SOCIAL CONTROL; STANDARD;

ANIMALS; ANTIBODIES; BIOLOGICAL PRODUCTS; DRUG INDUSTRY; HUMANS; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOCIAL CONTROL, FORMAL;

EID: 79952531972     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.121     Document Type: Conference Paper

References (8)

1. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98(9), 2909-2934 (2009).
2. Koren E, De Groot AS, Jawa V et al. Clinical validation of the ' in silico ' prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124(1), 26-32 (2007). (Pubitemid 46938690)
3. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2-3), 106-121 (2005). (Pubitemid 41712000)
4. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters infuencing the antigenicity of interferon a in normal and transgenic mice. Pharm. Res. 14(10), 1472-1478 (1997). (Pubitemid 27481082)
5. Shankar G, Pendley C, Stein K. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25 (5), 555-561(2007).
6. Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies Regul. Toxicol. Pharmacol. 54 (2), 164-182 (2009).
7. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281 (2008).
8. Joshi A, Bauer R, Kuebler P et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46, 10-20 (2006). (Pubitemid 43021710)